AMELIORATING JOINT CONDITIONS INCLUDING INJURIES AND DISEASES
20220296376 · 2022-09-22
Assignee
Inventors
Cpc classification
A61F2002/30563
HUMAN NECESSITIES
A61F2002/30759
HUMAN NECESSITIES
A61F2002/2817
HUMAN NECESSITIES
A61F2/2846
HUMAN NECESSITIES
A61F2002/30932
HUMAN NECESSITIES
A61F2002/30766
HUMAN NECESSITIES
A61F2/30771
HUMAN NECESSITIES
A61B17/562
HUMAN NECESSITIES
A61F2002/30841
HUMAN NECESSITIES
A61F2002/3085
HUMAN NECESSITIES
A61F2002/30131
HUMAN NECESSITIES
International classification
A61B17/56
HUMAN NECESSITIES
Abstract
A method for ameliorating joint conditions and diseases and preventing bone hypertrophy can include facilitating cartilage regrowth and preventing bone overgrowth to a damaged bone at a treatment site within a body joint to promote healing. The method can include providing a device having a first section comprising a joint-ward end having an inner surface and an outer surface and fenestrations between the inner and outer surfaces. A second section can include an opposing leading end and a lateral wall extending between the joint-ward end and the leading end. The leading end can be penetrated into the bone to a depth to substantially position:1) the joint-ward end in a cartilage zone or at a boundary/transition area; and 2) the second section in the bone. Bone overgrowth into the cartilage zone may be prevented within the body joint when the device is positioned at the treatment site.
Claims
1. A method of promoting healing in or adjacent to a portion of a bone layer at a treatment site within a body joint, the method comprising: providing an implantable device having a body formed of material, the implantable device comprising: an axis defining an axial direction of the device; a first section comprising: a joint-ward end having an inner surface and an outer surface spaced apart from one another along the axial direction of the device, the joint-ward end further having first fenestrations extending fully through the joint-ward end in a manner that includes extending between and through the inner surface of the joint-ward end and the convex or concave profile of the outer surface of the joint-ward end; and a second section arranged along the axial direction from the first section and comprising: an opposing leading end; and a lateral wall extending between the joint-ward end and the leading end, wherein the lateral wall is configured to engage the bone layer at the treatment site; penetrating the leading end into the bone layer to a depth; positioning the second section in the bone layer; and positioning the joint-ward end in a position to facilitate transmission through the first fenestrations into a cartilage zone by positioning the joint-ward end at a transition area substantially between a cartilage layer in the cartilage zone and the bone layer at the treatment site such that the joint-ward end is beneath the cartilage zone or otherwise not extending entirely through the cartilage zone.
2. The method of claim 1, wherein the lateral wall comprises threads configured to engage the bone layer at the treatment site.
3. The method of claim 1, wherein the lateral wall further comprises second fenestrations configured to promote osseointegration of the second section at the treatment site.
4. The method of claim 1, wherein the first fenestrations promote intracellular nutrient transmission; or wherein the joint-ward end is substantially positioned such that cartilage can grow through, around, and over the first fenestrations in the joint-ward end.
5. The method of claim 1, wherein the cartilage is articular cartilage; or wherein the bone layer is a cortical bone base plate.
6. The method of claim 1, wherein healing includes mitigating bone hypertrophy when the joint-ward end is positioned at the transition area so as to protect against forces applied to the body joint.
7. The method of claim 6, wherein mitigating bone hypertrophy includes preventing trabecular thickening of cancellous bone.
8. The method of claim 1, wherein the transition area is located substantially in a cortical bone base plate; or wherein the transition area is located substantially between cancellous bone and the cartilage zone.
9. The method of claim 1, wherein the device inhibits bone growth into the cartilage zone when the joint-ward end is positioned at the transition area; or wherein the device prevents bone fracture when the joint-ward end is positioned at the transition area thus protecting against forces applied to the body joint.
10. The method of claim 1, wherein at least one of: the body joint is a knee, shoulder, elbow, wrist, hip, spine ankle, or finger; or the treatment site includes a subchondral lesion.
11. The method of claim 1, wherein the joint is selected from the group consisting of an acetabulofemoral joint, an acromioclavicular joint, a femoropatellar joint, a femorotibial joint, a glenohumeral joint, a humeroradial joint, a humeroulnar joint, an interphalangeal joint, a metacarpal joint, a radioulnar joint and a talocrural joint.
12. The method of claim 1, wherein a thickness of cartilage regrowth at the treatment site is substantially uniform after healing; or wherein a thickness of cartilage regrowth at the treatment site is substantially the same as a thickness of healthy native cartilage adjacent the treatment site after healing.
13. The method of claim 1, wherein the device is made at least in part from titanium or alloys thereof.
14. The method of claim 1, wherein the device is made at least in part from non resorbable material.
15. The method of claim 1, wherein the device is made at least in part from polyether-ether-ketone (PEEK).
16. The method of claim 1, wherein the device is made at least in part from a partially absorbable material or a fully absorbable material.
17. The method of claim 1, wherein the device is made at least in part from and/or includes at least one of: biocompatible plastic; a biocomposite polymer; a metal; a metal alloy; carbon fiber; cobalt chrome; nitinol; polycaprolactone (PCL); polyether-ether-ketone (PEEK); tantalum; titanium foam metals; ceramics; ceramic composites; elastomer composites; elastomer-carbon fiber composites; chambered or fluid-filled materials; metal matrices; injectable gels; injectable composites with fluid and solid matrices; bone or bone-composite or allografts; crystal or hydroxyapatite materials; bioabsorbable composites; TCP; PLLA; silicone. biomaterial; biocompatible material; a biocomposite material; a biomimetic material; a bioactive material; a nanomaterial; a partially absorbable material; a fully absorbable material; a tissue forming material; a biphasic material; or a replaceable material.
18. The method of claim 1, wherein at least the outer surface of the joint-ward end is coated with hydroxyapatite.
19. The method of claim 1, wherein the first section and the second section are reversibly attached.
20. The method of claim 1, wherein the first section and the second section are fused together.
21. The method of claim 1, wherein the lateral wall further comprises second fenestrations on the second section, wherein the second fenestrations are between 300 microns and 1200 microns in size.
22. The method of claim 1, wherein the first fenestrations on the joint-ward end of the first section are between 100 microns to 800 microns in size to promote cartilage regrowth.
23. The method of claim 1, wherein the joint-ward end is positioned at a boundary of the transition area, said boundary being located substantially between a cancellous bone and the cartilage zone.
24. The method of claim 1, wherein the joint-ward end forms a shape that substantially recreates the shape of a normal articulation surface on the bone after implantation when the joint-ward end is positioned at the treatment site.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] These and other features, aspects and advantages of the present invention will become better understood with regard to the following description, appended claims, and accompanying figures where:
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
DETAILED DESCRIPTION OF THE INVENTION
[0041] According to one embodiment of the present invention, there is provided a device for ameliorating joint conditions and diseases. According to another embodiment of the present invention, there is provided a method for ameliorating a joint condition or disease in a patient. In one embodiment, the method comprises providing a device according to the present invention. The device and methods will now be disclosed in detail.
[0042] As used in this disclosure, except where the context requires otherwise, the term “comprise” and variations of the term, such as “comprising,” “comprises” and “comprised” are not intended to exclude other additives, components, integers or steps.
[0043] As used in this disclosure, except where the context requires otherwise, the method steps disclosed and shown are not intended to be limiting nor are they intended to indicate that each step is essential to the method or that each step must occur in the order disclosed but instead are exemplary steps only.
[0044] All dimensions specified in this disclosure are by way of example only and are not intended to be limiting, except where the context requires otherwise. Further, the proportions shown in these Figures are not necessarily to scale. As will be understood by those with skill in the art with reference to this disclosure, the actual dimensions and proportions of any device or part of a device disclosed in this disclosure will be determined by its intended use.
[0045] According to one embodiment of the present invention, there is provided a device for ameliorating joint conditions and diseases. Referring now to
[0046] The first section 12 of the device 10 comprises a joint-ward end 16, an opposing mating end 18, and a lateral wall 20 extending between the joint-ward end 16 and the mating end 18. The first section 12 further comprises a diameter (d-d) and an axial length (b-b). In one embodiment, the diameter (d-d) is between 5 mm and 30 mm. In another embodiment, the diameter (d-d) is between 5 mm and 20 mm. In another embodiment, the diameter (d-d) is between 8 mm and 16 mm. In a preferred embodiment, the diameter (d-d) is 8 mm. In another preferred embodiment, the diameter (d-d) is 12 mm. In another preferred embodiment, the diameter (d-d) is 16 mm. In one embodiment, the axial length (b-b) is between 0.5 mm and 2.5 mm. In another embodiment, the axial length (b-b) is between 1 mm and 2 mm. In a preferred embodiment, the axial length (b-b) is 1.25 mm.
[0047] In one embodiment, the first section 12 further comprises a peripheral column 22 partially forming the lateral wall 20, a central column 24, and three or more than three struts 26, each strut 26 extending between and connecting the peripheral column 22 and the central column 24, and each strut 26 thereby supporting the central column 24.
[0048] In one embodiment, the joint-ward end 16 further comprises a plurality of fenestrations 28, where each fenestration 28 is formed by a confluence of the peripheral column 22, the central column 24, and two adjacent struts 26 of the three or more than three struts 26. Each fenestration 28 can comprise any shape suitable for the intended purpose of the device 10, as will be understood by those with skill in the art with respect to this disclosure. In one embodiment, as shown particularly in
[0049] The first section 12 further comprises a central aperture 30 within and formed by the central column 24. The central aperture 30 can extend axially completely through the joint-ward end 16 as shown particularly in
[0050] In one embodiment, peripheral column 22 of the first section 12 comprises one or more than one notch 34 as seen in
[0051] The joint-ward end 16 of the first section 12 of the device 10 performs a partial load-bearing function after implantation, and comprises a shape suitable to substantially match the shape of the articulation surface that the device 10 recreates on the bone after implantation, as will be understood by those with skill in the art with respect to this disclosure. Therefore, the joint-ward end 16 can have either a convex profile as seen on a cross-sectional, lateral perspective view, as shown in
[0052] The lateral wall 20 of the first section 12 can be any shape suitable for the intended purpose of the device 10, as will be understood by those with skill in the art with respect to this disclosure. In a preferred embodiment, the lateral wall 20 of the first section 12 comprises a generally convex profile as seen on a cross-sectional, lateral perspective view, as shown in
[0053] The device 10 further comprises a second section 14. The second section 14 of the device 10 comprises a mating end 36, an opposing leading end 38, and a lateral wall 40 extending between the mating end 36 and the leading end 38. The second section 14 further comprises an axial length (c-c). In one embodiment, the axial length (c-c) is between 5 mm and 30 mm. In another embodiment, the axial length (c-c) is between 5 mm and 20 mm. In another embodiment, the axial length (c-c) is between 6 mm and 15 mm. In a preferred embodiment, the axial length (c-c) is 6 mm. In another preferred embodiment, the axial length (c-c) is 10 mm. In another preferred embodiment, the axial length (c-c) is 15 mm. In one embodiment, the lateral wall 40 of the second section 14 is generally cylindrical as seen in
[0054] The mating end 36 of the second section 14 of the device 10 is configured to mate with the mating end 18 of the first section 12 of the device 10. The mating end 18 of the first section 12 and the mating end 36 of the second section 14 can comprise any mating mechanism suitable for the intended purpose of the device 10 can be used, as will be understood by those with skill in the art with respect to this disclosure. In one embodiment, the mating end 18 of the first section 12 and the mating end 36 of the second section 14 mate by a suitable biocompatible adhesive, as will be understood by those with skill in the art with respect to this disclosure. In a preferred embodiment, the mating mechanism is reversible, allowing an interchange of an alternate first section 12 to a specific second section 14 so that the device 10 can be reconfigured as needed for contouring to a particular joint surface, thereby decreasing the number of second sections 14 that need to be stored on site, as will be understood by those with skill in the art with respect to this disclosure. In one embodiment, the mating end 18 of the first section 12 and the mating end 36 of the second section 14 mate by a reversible twist locking mechanism, as will be understood by those with skill in the art with respect to this disclosure. In another embodiment, the first section 12 and the second section 14 are made as a unified whole as shown in
[0055] The leading end 38 of the second section 14 of the device 10 is configured to place the device 10 into a prepared space made according to a method according to the present invention. In one embodiment, the leading end 38 comprises a scalloped edge 42. In another embodiment, the leading end 38 comprises bevels 44. In a preferred embodiment, the leading end 38 comprises both a scalloped edge 42 and bevels 44 as shown particularly in
[0056] The lateral wall 40 of the second section 14 of the device 10 extends between the mating end 36 and the leading end 38. The lateral wall 40 of the second section 14 comprises threads 46 for anchoring the device 10 within the bone. In one embodiment, the lateral wall 40 of the second section 14 further comprises a plurality of fenestrations 48 between the threads 46. In a preferred embodiment, the device 10 further comprises a plurality of fenestrations 50 formed by a confluence of the mating end 18 of the first section 12 and the mating end 36 of the second section 14. Each fenestration 48, 50 can comprise any shape suitable for the intended purpose of the device 10, as will be understood by those with skill in the art with respect to this disclosure. In a preferred embodiment, each fenestration 48, 50 is oval or round. In one embodiment, the lateral wall 40 of the second section 14 is textured to promote bony ingrowth after implantation, as will be understood by those with skill in the art with respect to this disclosure.
[0057] The first section 12 and the second section 14 can comprise any material suitable for the intended purpose of the device 10, as will be understood by those with skill in the art with respect to this disclosure. In one embodiment, the first section 12 comprises a material selected from the group consisting of a biocompatible plastic, a biocomposite polymer, a metal and a metal alloy. In one embodiment, the first section 12 comprises a material selected from the group consisting of carbon fiber, cobalt chrome, nitinol, polycaprolactone (PCL), polyether-ether-ketone (PEEK), tantalum and titanium. In one embodiment, the second section 14 comprises a material selected from the group consisting of a biocompatible plastic, a biocomposite polymer, a metal and a metal alloy. In one embodiment, the second section 14 comprises a material selected from the group consisting of carbon fiber, cobalt chrome, nitinol, polycaprolactone (PCL), polyether-ether-ketone (PEEK), tantalum and titanium. In one embodiment, the first section 12 comprises a first material and the second section 14 comprises a second material, where the first material and the second material are the same material. In another embodiment, the first section 12 comprises a first material and the second section 14 comprises a second material, where the first material and the second material are the different materials.
[0058] In one embodiment, the device 10 further comprises an insert 52. Referring now to
[0059] The device 10 can be made by any suitable method, as will be understood by those with skill in the art with respect to this disclosure. In one embodiment, the first section 12 and the second section 14 are machined from modular parts such as by direct metal laser sintering, as will be understood by those with skill in the art with respect to this disclosure.
[0060] According to another embodiment of the present invention, there is provided a method for ameliorating a joint condition or disease in a patient. Referring now to
[0061] The method comprises identifying a patient with a joint condition or disease that is suitable for treatment by the present method, where the joint comprises a bone with a surface comprising a defect caused by the joint condition or disease. As will be understood by those with skill in the art with respect to this disclosure, the joint can be any joint with a hyaline cartilage bearing surface, joint capsule, and synovial fluid. In one embodiment, the joint is a diarthrodial joint (also known as a synovial joint). In one embodiment, the joint is selected from the group consisting of an acetabulofemoral joint, an acromioclavicular joint, a femoropatellar joint, a femorotibial joint, a glenohumeral joint, a humeroradial joint, a humeroulnar joint, an interphalangeal joint, a metacarpal joint, a radioulnar joint and a talocrural joint. In one embodiment, the patient is a human. In one embodiment, the patient is a non-human animal. In a preferred embodiment, the joint condition and disease is selected from the group consisting of arthroses, chondromalacia patella, isolated chondral defect, juvenile idiopathic arthritis, ligamentous deficiency arthroses, osteoarthritis (degenerative arthritis or degenerative joint disease), osteonecrosis, osteochondritis dissecans, patellar instability, post-ligamentous injury arthritis, post-meniscectomy arthritis, post-meniscectomy arthroses, post-traumatic arthritis, rheumatoid arthritis and septic arthritis. In one embodiment, identifying the patient comprises diagnosing the patient with a joint condition and disease. In one embodiment, diagnosing the patient comprises performing one or more than one of action selected from the group consisting of performing a physical examination, performing a non-invasive imaging examination (such as magnetic resonance imaging, computerized tomography and ultrasound) and performing arthroscopy. In another embodiment, identifying the patient comprises consulting patient records to determine if the patient has a joint condition or disease suitable for treatment by the present method.
[0062] Next, the method further comprises accessing the joint 100. In one embodiment, accessing the joint 100 is accomplished by arthroscopy. In another embodiment, accessing the joint 100 is accomplished by an open surgical procedure, such as for example a mini-open procedure.
[0063] In one embodiment, as shown in
[0064] Then, the method further comprises placing a guidepin 114 within the center of the defect 102 as shown in
[0065] Next, the method further comprises creating a space 116 in the defect 102 of the bone for a device. In one embodiment, the space 116 is created using a bone reamer 118 placed over the guidepin 114 to core and plane the surface of the defect 102 as shown in
[0066] In one embodiment, the method further comprises creating one or more than one vascular channel in the bone deep to the space 116 using a drill bit guide 120 positioned over the guidepin 114 and a drill bit 122 passed within the drill bit guide 120 as shown in
[0067] Next, the method further comprises providing a first device 126 for ameliorating joint conditions and diseases suitable for ameliorating the joint condition or disease of the patient as can be seen in
[0068] In one embodiment, the method further comprises injecting a biologic material, such as for example stem cells or platelet rich plasma, or both stem cells and platelet rich plasma 130 into the first device 126 using an injector 132 as shown in
[0069] Then, the method further comprises screwing the first device 126 into the space 116 using the driver 128, as shown in
[0070] In one embodiment, as can be seen in
[0071]
[0072] Under natural healing conditions without medical intervention, the cortical bone base plate 138 tends to grow past a boundary/transition 143 of the cartilage zone 139 in a direction 142 toward the articulating body joint at the injury site 141 as shown in
[0073] An embodiment of the present invention includes a new, useful and non-obvious method of facilitating cartilage regrowth and preventing bone overgrowth to a damaged bone at a treatment site within a body joint to promote healing and avoid the scenario described above and shown in
[0074] With reference to
[0075] Advantageously, the device 10 is positioned and configured to provide active or passive dampening support to the bone at the treatment/injury site 141 so as to dissipate and dampen shock within the bone to promote healing. This may prevent excessive thickening of the cancellous bone. The second section 14 includes fenestrations 48 and these fenestrations are configured to promote osseointegration of the second section at the treatment site. This provides stability. Furthermore, as discussed in U.S. Patent Application 62/260,030, entitled “Methods, Systems, and Devices for Repairing Anatomical Joint Conditions” filed on Nov. 25, 2015, which is pending, the contents of which are incorporated herein by reference, the fenestrations may have different porosities targeted to promote specific tissue growth and differentiation. For example, the fenestrations may be different sizes conducive to facilitating cartilage regrowth on outer surface 16b of the joint-ward end 16 and to prevent bone overgrowth into the cartilage zone 139 within the body joint on the inner surface 16a of the joint-ward end 16. The joint-ward end 16 may be substantially positioned at a boundary/transition area 143 between a cartilage layer and a bone layer such that cartilage can grow through and around and even over the top of the fenestrations 28 in the joint-ward end 16. The transition area 143 may be located substantially in a cortical bone base plate or located substantially between cancellous bone and a cartilage zone, for example.
[0076] The plurality of fenestrations between the protrusions (e.g. treads, notches) 46 on the second section of the lateral wall are between about 300 microns and 1200 microns in size to promote bone growth while the plurality of fenestrations on the joint-ward end of the first section are between about 100 microns to 800 microns in size to promote cartilage growth. Preferably, the plurality of fenestrations on the joint-ward end 16 of the first section are between about 400 microns to 800 microns in size to promote cartilage growth. Circular pores, pie-shaped fenestrations and other shapes are considered.
[0077] Though the method of the present invention has been disclosed with respect to a defect 102 in a femorotibial joint 100, corresponding methods can be used with other joints.
[0078] Although the present invention has been discussed in considerable detail with reference to certain preferred embodiments, other embodiments are possible. Therefore, the scope of the appended claims should not be limited to the description of preferred embodiments contained in this disclosure.